Apr 26, 2007
|
Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences
|
|
Apr 14, 2007
|
Interim Results Presented at EASL from PROVE 1 Clinical Trial of Investigational Drug Telaprevir in Patients with Genotype 1 Hepatitis C
|
|
Apr 11, 2007
|
Vertex Pharmaceuticals Announces New Data for Investigational HCV Protease Inhibitor Telaprevir to be Presented at 42nd Annual Meeting of the European Association for the Study of the Liver (EASL)
|
|
Mar 07, 2007
|
Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences
|
|
Mar 05, 2007
|
Vertex Pharmaceuticals Announces Completion of Conversion of Outstanding 5.75% Convertible Senior Subordinated Notes due 2011
|
|
Feb 22, 2007
|
Vertex Pharmaceuticals Announces Webcast of its Presentation at the Bear Stearns Ninth Annual London Healthcare Conference
|
|
Feb 05, 2007
|
Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences
|
|
Feb 02, 2007
|
Vertex Pharmaceuticals Announces Redemption Date for 5.75% Convertible Senior Subordinated Notes due 2011
|
|
Feb 01, 2007
|
Vertex Pharmaceuticals Reports 2006 Financial Results
|
|
Jan 24, 2007
|
Vertex Pharmaceuticals Announces Webcast of its Presentation at the Wachovia Securities Small and Mid-Cap Healthcare Conference
|
|
Jan 08, 2007
|
Vertex Pharmaceuticals Announces 2007 Business Objectives at 25th Annual JPMorgan Healthcare Conference
|
|
Jan 08, 2007
|
Vertex Pharmaceuticals Announces 2007 Business Objectives at 25th Annual JPMorgan Healthcare Conference
|
|
Dec 21, 2006
|
Merck and Vertex Announce Start of Pivotal Phase 2 Clinical Trial for Investigational Aurora Kinase Inhibitor MK-0457 (VX-680) in Patients with Treatment-Resistant Forms of Advanced Leukemias
|
|
Dec 13, 2006
|
Pharmaceuticals Announces Results of First Interim Safety and Antiviral Analysis of the PROVE 1 Clinical Trial of Investigational HCV Protease Inhibitor Telaprevir (VX-950)
|
|
Dec 11, 2006
|
Merck and Vertex Announce Phase I Results for Investigational Aurora Kinase Inhibitor MK-0457 (VX-680); Compound Showed Activity in Patients with Treatment-Resistant Forms of Advanced Leukemias and Myeloproliferative Disorders
|
|
Dec 11, 2006
|
Vertex Pharmaceuticals Added to NASDAQ-100 Index
|
|
Oct 27, 2006
|
New Data for Investigational Hepatitis C Drug Telaprevir (VX-950) to be Presented at AASLD Meeting
|
|
Oct 26, 2006
|
Vertex Pharmaceuticals Reports Third Quarter 2006 Financial Results
|
|
Sep 28, 2006
|
Vertex Pharmaceuticals and GlaxoSmithKline Announce Virologic and Drug Resistance Results from Protease Inhibitor Study
|
|
Sep 20, 2006
|
Vertex Pharmaceuticals Announces Completion of Common Stock Offering
|
|